(a) Cyclotek NSW Pty Ltd acquires the business from Cyclopet Pty Ltd (a subsidiary of Cyclopharm Ltd) the cyclotron facility at Macquarie University.
(b) Cyclotek (Aust) Pty Ltd signed a technology transfer agreement with Bristol Myers Squibb for their immunotherapy tracer. The development is being translated onto a GE Fastlab 2 synthesis with dual pHPLC systems.
(c) Completion of the validation for 18F FP-CIT a radiopharmaceutical used to image dopamine transporter. This radiopharmaceutical has been found to be clinically useful, as Parkinson Disease is neurodegenerative because of the loss of dopaminergic nerve terminals along the nigrostriatal pathway.
(d) The Prostate Specific Radiopharmaceutical, 18F-DCFPyL has now been validated at our Lucas Heights facility. This now adds to our sites in Queensland and Victoria enabling supply through-out the East Coast, Tasmania, Adelaide and New Zealand.
(e) Cyclotek’s CMO, Dr Rob Ware submitted an application into the Medical Services Advisory Committee for MBS funding of PET/CT PSMA imaging. Currently PSMA PET/CT imaging services are being widely used and men with Prostate Cancer are paying for this service as an out of pocket cost.
[contact-form-7 id=”714″ title=”Update Form”]